Foghorn Therapeutics Inc(FHTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.02 | Insider Own | 46.74% | Shs Outstand | 58.7M | Perf Week | 3.98% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | 9.71% | Insider Trans | - | Shs Float | 31.6M | Perf Month | -41.46% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.25 | Inst Own | 47.65% | Short Float | 7.76% | Perf Quarter | -53.86% |
| Income | -0.06B | P/S | 3.38 | EPS this Y | 23.04% | Inst Trans | 1.1% | Short Ratio | 3.45 | Perf Half Y | -56% |
| Sales | 0.04B | P/B | - | EPS next 5Y | 14.13% | ROA | -30.06% | Short Interest | 2.46M | Perf YTD | -61.3% |
| Book/sh | -1.38 | P/C | 0.74 | EPS past 3/5Y | 23.34% 8.8% | ROE | - | 52W High | -72.54% ($7.61) | Perf Year | -50.59% |
| Cash/sh | 2.82 | P/FCF | - | Sales past 3/5Y | 17.14% 135.14% | ROIC | - | 52W Low | 16.76% ($1.79) | Perf 3Y | -37.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 17.68% | Gross Margin | 94.18% | Volatility(W/M) | 6.12% 12.28% | Perf 5Y | -83.53% |
| Dividend TTM | - | EV/Sales | -0.01 | Sales Y/Y TTM | 51.98% | Oper. Margin | -186.38% | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.36 | EPS Q/Q | 64.26% | Profit Margin | -175.78% | RSI (14) | 30.68 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.36 | Sales Q/Q | 112.68% | SMA20 | 5.26% ($1.99) | Beta | 3.15 | Target Price | $5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -43.54% ($3.7) | Rel Volume | 0.56 | Prev Close | $2.13 |
| Employees | 106 | LT Debt/Eq | - | EPS/Sales Surpr. | 59.18% 136.38% | SMA200 | -55.81% ($4.73) | Avg Volume(3M) | 0.71M | Price | $2.09 |
| IPO | 2020/10/23 | Option/Short | Yes/Yes | Trades | 1569 | Volume | 396,992 | Change | -1.88% |
Chromatin biology (gene transcription regulation)-based precision oncology biotech developing novel cancer therapies. The company uses its proprietary discovery platform to develop candidates targeting chromatin regulatory proteins such as SMARCA2, and is a clinical-stage biotech with multiple programs in preclinical and early clinical stages.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
FHTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +23.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $338. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 47.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #339 of 594 in the industry
Based on market cap of $124M.
FHTX#339 Foghorn Therapeutics Inc $124M PER - 
ARMP#340 Armata Pharmaceuticals Inc $121M PER - 
AVXL#341 Anavex Life Sciences Corp $121M PER - 
OTLK#342 Outlook Therapeutics Inc $120M PER - 
NKTX#343 Nkarta Inc $119M PER - 
FAQ
What kind of company is FHTX?
FHTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FHTX?
The market cap of FHTX is approximately $124M, ranking 4,352 within its sector.
What is the 52-week high and low for FHTX?
FHTX has recorded a 52-week high of $7.61 and a low of $1.79.
